Sumatriptan/naproxen

Sumatriptan/naproxen
Combination of
SumatriptanTriptan
NaproxenNonsteroidal anti-inflammatory drug (NSAID)
Clinical data
Trade namesTreximet, Suvexx, others
AHFS/Drugs.comMonograph
License data
Routes of
administration
By mouth
ATC code
  • None
Legal status
Legal status
Identifiers
KEGG

Sumatriptan/naproxen, sold under the brand name Treximet among others, is a fixed-dose combination medication used to treat migraines.[2] It is taken by mouth.[2] It contains sumatriptan, as the succinate, a serotonin 5-hydroxytryptamine (5-HT) 1b/1d receptor agonist (triptan); and naproxen as the sodium salt, a member of the arylacetic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs).[2]

Medical uses

Sumatriptan/naproxen is indicated for the acute treatment of migraine with or without aura in people twelve years of age and older.[2]

A Cochrane review in 2020 found that the combination of sumatriptan plus naproxen was better than placebo for relieving acute migraine attacks in adults. When the starting headache intensity was mild, 5 in 10 (50%) of people treated with the combination were pain-free at two hours compared with about 2 in 10 (18%) with placebo. Almost 6 in 10 (58%) people with moderate or severe pain who were treated with the combination had pain reduced to mild or none at two hours, compared with 3 in 10 (27%) with placebo. The combination was also better than the same dose of either drug given alone in these people. Results were 5 in 10 (52%) people with sumatriptan alone or about 4 in 10 (44%) with naproxen alone.[3]

Side effects

Some of the listed side effects include dizziness, nausea, sleepiness, dry mouth, pain in neck, throat or jaw, numbness or tingling.[4]

References

  1. "Regulatory Decision Summary - Suvexx". Health Canada. 23 October 2014. Retrieved 7 June 2022.
  2. 1 2 3 4 5 "Treximet- sumatriptan succinate and naproxen sodium tablet, film coated". DailyMed. 14 April 2022. Retrieved 7 June 2022.
  3. Law S, Derry S, Moore RA (April 2016). "Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults". The Cochrane Database of Systematic Reviews. 4 (4): CD008541. doi:10.1002/14651858.CD008541.pub3. PMC 6485397. PMID 27096438.
  4. "Treximet". Drugs.com.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.